TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00016458
Drug: anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00540891
Drug: ALFUZOSIN
Normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01264939
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
Study: NCT01264939
Drug: H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
Study: NCT01264939
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
Study: NCT01454076
Drug: Ixazomib 2.5 mg
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib 2.5 mg Capsule B (Cycle 1 only)
Study: NCT01454076
Drug: Ixazomib 4 mg Capsule A
Normalized name: ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib 4 mg Capsule A (Cycle 1 only)
Study: NCT01454076
Drug: Ixazomib 4 mg Capsule B
Normalized name: ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib 4 mg Capsule B (Cycle 2 and beyond )
Study: NCT01454076
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole 400 mg tablets (Cycle 1 only)
Study: NCT01454076
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg capsule (Cycle 1 only)
Study: NCT01454076
Drug: Ixazomib 4 mg Capsule B
Normalized name: ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib 4 mg Capsule B (Cycle 1 and beyond)
Study: NCT02653196
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab 12 mg/m2 IV: 2 doses (not given if matched related donor is 10/10 HLA matched sibling donor)
Study: NCT02653196
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thiotepa 300 mg/m2 IV: 3 doses
Study: NCT02653196
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 100 mg/m2 IV: 3 doses
Study: NCT02653196
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/m2 IV: 3 doses
Study: NCT02653196
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 70 mg/m2 IV: Day 2 doses
Study: NCT02653196
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 0.05 mg/kg/day IV (Cyclosporine may be substituted for Tacrolimus): Start Day -2, begin taper on Day +100, discontinue on Day +180
Study: NCT02653196
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A dosed as follows: Age ≤ 6 years: 6 mg/kg/day IV in divided doses (e.g. 2 mg/kg every 8 hours) OR Age \> 6 years: 3 mg/kg/day IV in divided doses (1.5 mg/kg every 12 hours): Start Day -2, begin taper on Day +100, discontinue on Day +180
Study: NCT02653196
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 15 mg/kg every 8 hours oral or IV: Start Day 0 (4-6 hours post stem cell infusion) to Day +40, then taper weekly until discontinuation on Day +90
Study: NCT02984176
Drug: Simethicone Tab 40 mg
Normalized name: simethicone Chewable Tablet
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets of Simethicone Tab 40 mg (one tablet after each meal) and to fast overnight the day before the operation.
Study: NCT01823029
Drug: erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01401491
Drug: clozapine plus fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clozapine 100 mg/day plus fluvoxamine 50 mg/day
Study: NCT01401491
Drug: clozapine plus placebo
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clozapine 300 mg/day plus placebo
Study: NCT01302964
Drug: Mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg per week for subjects weighing less than 50 kg and up to 15 mg per week for subjects weighing more than 50 kg depending on efficacy and tolerability.
Study: NCT00287911
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36
Study: NCT00287911
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenously continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36 -Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined
Study: NCT01478698
Drug: Tissue Plasminogen Activator (tPA)
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tPA 10mg per dose intraperitoneal
Study: NCT01478698
Drug: recombinant deoxyribonuclease (DNase)
Normalized name: Recombinant deoxyribonuclease (DNAse)
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DNase 5mg per dose given intraperitoneally.
Study: NCT02426281
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.
Study: NCT02426281
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
Study: NCT02674412
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02376192
Drug: Spinal Anesthesia- Bupivacaine
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The spinal anesthetic technique is standardized. In the operating room spinal anesthesia will be administered with the L2-L5 interspaces in the sitting position using 12 mg of hyperbaric bupivacaine with 15 mcg of fentanyl and 150 mcg of preservative free morphine.
Study: NCT02376192
Drug: Bolus Phenylephrine/Ephedrine Treatment
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who experience hypotension following induction of spinal anesthesia will be treated with a bolus of phenylephrine and/or ephedrine as needed.
Study: NCT02376192
Drug: Phenylephrine Infusion
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
Study: NCT03466502
Drug: Oral Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin will be given concurrently with antibiotics to hospitalized patients with a history of Clostridium difficile infection to prevent recurrence
Study: NCT03671603
Drug: Iodixanol
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol 270 mgI/ml or 320 mg I/ml injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
Study: NCT00315276
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04385602
Drug: Intratracheal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thirty minutes before the end of the surgery, Dex (0.5μg/kg diluted and mixed in 1ml saline in a medical spray bottle) will be sprayed down the intratracheal tube
Study: NCT04385602
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thirty minutes before the end of the surgery, 1ml saline in a medical spray bottle will be sprayed down the intratracheal tube
Study: NCT02433834
Drug: Glycopyrronium MDI
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI
Study: NCT01957956
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03251326
Drug: Nabilone
Normalized name: Nabilone
DrugBank: Nabilone (DB00486)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nabilone capsules (4 mg)
Study: NCT03251326
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes (0.0 and 5.6% THC)
Study: NCT03251326
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol capsules (40mg)
Study: NCT00772096
Drug: n-3 fatty acids
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02209766
Drug: D5884
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1st cohort: Dose 1(2g) D5884(n=6) in Japanese 2nd cohort: Dose 2(4g) D5884(n=6) in Japanese 3rd cohort: Dose 2(4g) D5884(n=6) in Caucasian
Study: NCT00507247
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6mg/kg/day IV for at least 10 days.
Study: NCT00596011
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.
Study: NCT02720926
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin: 130mg/m2 day 1 every 21days
Study: NCT00215774
Drug: Flecainide
Normalized name: Flecainide
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
Study: NCT01166594
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intrableb injection
Study: NCT01166594
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intrableb BSS injection
Study: NCT04118010
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 50,000 IU /week for 12 weeks
Study: NCT04118010
Drug: Placebo vitamin D3
Normalized name: vitamin D3
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching to Vitamin D3 placebo capsules for 12 weeks
Study: NCT04118010
Drug: Inulin
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chicory-derived prebiotic inulin 12 g/day for 12 weeks
Study: NCT04118010
Drug: Placebo Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Corn-derived maltodextrin 12g/day as the prebiotic placebo for 12 weeks
Study: NCT00599937
Drug: ATRA
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: early introduction of ATRA
Study: NCT00599937
Drug: ATRA and or Chemo as maintenance
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group
Study: NCT02607488
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]
Study: NCT02607488
Drug: Lidocaine 1.5%
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1.5% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]
Study: NCT02607488
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]
Study: NCT04613180
Drug: Montelukast Sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older.
Study: NCT01163604
Drug: Argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment
Study: NCT01163604
Drug: non-argatroban treated group
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
Study: NCT04659070
Drug: Active comparator2 : Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 80mg PO, Once daily for 8 weeks
Study: NCT03191539
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation
Study: NCT00054561
Drug: isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03955367
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin based concurrent chemotherapy, including cisplatin as a single agent or cisplatin plus Paclitaxel.
Study: NCT00762346
Drug: zometa
Normalized name: Zometa
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zometa 4mg i.v. every 4 weeks for up to 2 years
Study: NCT04504942
Drug: Leronlimab
Normalized name: Leronlimab
DrugBank: Leronlimab (DB05941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Leronlimab 525mg
Study: NCT01595360
Drug: TT-173
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is applied directly to the bleeding site after tooth extraction
Study: NCT02995915
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
Study: NCT04088461
Drug: Linagliptin / Metformin Oral Tablet
Normalized name: linagliptin / metformin Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Linagliptin 2.5 mg + Metformin 850 mg twice daily plus a lifestyle modifications program
Study: NCT04088461
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 850 mg twice daily plus lifestyle modifications program
Study: NCT02896127
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: 4x 150 mg Secukinumab s.c. weekly~Maintenance: 150 mg Secukinumab s.c. monthly~All Subjects received blinded treatment weekly starting at baseline, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4 until Week 16. At Week 16, Group 1 patients continued using secukinumab 150 mg and Group 2 patients started receiving secukinumab 150 mg dosing every four weeks. Treatment was provided open-label from Week 16 onward, as all patients took 150 mg s.c. every 4 weeks; however, subjects, investigators, and site staff remained blinded to initial randomized group assignment.
Study: NCT00049387
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00049387
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02481505
Drug: Chloroprocaine HCl 1%
Normalized name: CHLOROPROCAINE HCL 1% INJ
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal Route
Study: NCT01425099
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
Study: NCT01425099
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone is a commonly used corticosteroid used for a variety of medical condiitons
Study: NCT00552110
Drug: OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFNS 2 sprays per nostril with OXY 1 spray per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening (PM).
Study: NCT00552110
Drug: OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFNS 2 sprays per nostril with OXY 3 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening.
Study: NCT00552110
Drug: mometasone furoate nasal spray (MFNS) once daily
Normalized name: mometasone furoate Nasal Spray
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFNS 2 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every morning (AM) and every evening.
Study: NCT00552110
Drug: oxymetazoline nasal spray (OXY) twice daily
Normalized name: oxymetazoline Nasal Spray
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OXY 2 sprays per nostril twice daily x 2 weeks. Matching placebo to MFNS given every morning.
Study: NCT06418620
Drug: Venglustat
Normalized name: Venglustat
DrugBank: Venglustat (DB14966)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet-Route of administration:Oral
Study: NCT02920060
Drug: Intravenous levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous levetiracetam(30mg/kg bolus followed by 20mg/kg/dose IV 12 hourly).
Study: NCT02920060
Drug: Sodium valproate
Normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous sodium valproate(20mg/kg bolus followed by 10 mg/kg/dose IV 8hrly)
Study: NCT01628926
Drug: Ropinirole
Normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ropinirole oral administration TID up to 15.0 mg/day
Study: NCT02549027
Drug: MK-1064
Normalized name: MK-1064
DrugBank: MK-1064 (DB15028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral MK-1064 tablets (10 and 50 mg strengths)
Study: NCT00003141
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00003141
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00003141
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00003141
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00003141
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02382094
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00938730
Drug: YM150
Normalized name: Yohimbine
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00938730
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00454207
Drug: sildenafil citrate (UK-92,480)
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sildenafil citrate (UK-92,480)
Study: NCT01672957
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Protocol does not specify any regimen for treatment. The choice of treatment will be made prior to enrollment by the treating physician.